The mAbs remain the most favored and hence, the fastest-growing segment of the global protein therapeutics market. Considering their wide offerings ranging from rare diseases to generic and chronic ones, the vendors find immense growth opportunities to be tapped in the segment. Because of this, since the launch of the first mAb in 1986, the protein therapeutics market at present witnesses the availability of many antibodies ranging from oncology indications to autoimmune diseases as well as rare diseases like hemophilia and cystic fibrosis.

PART 01: Executive summary

Alternate therapies hinder the growth possibilities of approved therapies

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Highlights

PART 05: Market landscape

Market overview

Five forces analysis

PART 06: Market segmentation by product type

Global mAbs market

Global human insulin market

Global clotting factors market

Global EPO market

Global human growth hormone market

PART 07: Market segmentation by therapy area

Metabolic and endocrine disorders

Hematopoiesis

Fertility

Cancer

Autoimmune diseases

Infectious diseases

Protein vaccine

PART 08: Market segmentation by protein function

Enzymatic and regulatory activity

Special targeting activity

Vaccines

Protein diagnostics

PART 09: Geographical segmentation

Protein therapeutics market in Americas

Protein therapeutics market in EMEA

Protein therapeutics market in APAC

PART 10: Market drivers

Increased demand for mAbs

Development of novel therapies using innovative

technologies

Availability of favorable reimbursement policies

PART 11: Impact of drivers

PART 12: Market challenges

Complexities in manufacturing, storage conditions,

distribution policies, and high cost

Complicated regulatory framework

Alternate therapies loom large

PART 13: Impact of drivers and challenges

PART 14: Market trends

Emergence of next-generation biologics

Advent of biosimilars expected to improve the treatment

rates

Strategic alliances further boost the R&D efforts

PART 15: Vendor landscape

Competitive scenario

Market share analysis 2016

Other prominent vendors

PART 16: Key vendor analysis

F. Hoffmann-La Roche

Novo Nordisk

Amgen

AbbVie

Johnson & Johnson

Merck

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio